Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.210 -0.010 (-0.82%)
Streaming Delayed Price Updated: 12:18 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
From Fate Therapeutics, Inc.
Via GlobeNewswire
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Via Benzinga
Forecasting The Future: 8 Analyst Projections For Fate Therapeutics
Via Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Where Fate Therapeutics Stands With Analysts
Via Benzinga
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
Via Benzinga
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Recap: Fate Therapeutics Q4 Earnings
Via Benzinga
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024
FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Present at Upcoming March Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS